5.87
-0.51%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Eikon Therapeutics, Inc. Common Stock
From its filings with the US Securities and Exchange Commission
Eikon Therapeutics, Inc. Common Stock is based in Millbrae, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker EIKN. The SEC classifies its business as biological products, (no diagnostic substances).
We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers.
Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab, currently the world’s best-selling oncology therapeutic and arguably the most important anti-neoplastic agent ever introduced into clinical practice. While Drs. Perlmutter and Baynes’ track records do not provide a guarantee of future clinical success, and any products developed by us may not achieve the regulatory or commercial success of products that Drs.
Quoted from its 10-K, filed 30 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Listed since
- 5 Feb 2026
- Website
- eikontx.com ↗
- Head office
- 230 HARRIET TUBMAN WAY, MILLBRAE, CA, 94030
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- <br>Emerging growth company
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- EIK1001 activates innate and adaptive immune responses for anti-tumor treatment.
- EIK1003 and EIK1004 target ovarian, breast, prostate, and pancreatic cancers selectively.
- EIK1005 is a potent WRN helicase inhibitor for MSI-high tumors.
Weaknesses
- EIK1006 is a clinical candidate with activity against multiple androgen receptor variants.
- EIK1004 addresses brain metastases and primary brain malignancies specifically.
- EIK1003 and EIK1004 are selective PARP1 inhibitors for various cancers.
Opportunities
- EIK1001 targets systemic TLR 7/8 dual-agonist for immune activation.
- EIK1005 targets MSI-high tumors with a potent WRN helicase inhibitor.
- EIK1006 is a next-generation androgen receptor antagonist for multiple variants.
Threats
- EIK1004 is a brain-penetrant inhibitor for brain metastases treatment.
- EIK1003 and EIK1004 are selective PARP1 inhibitors for multiple cancer types.
- EIK1005 is a WRN helicase inhibitor for MSI-high tumor treatment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.